FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia
09 juin 2015 18h47 HE
|
SANOFI
PARIS and TARRYTOWN, N.Y., June 9, 2015 (GLOBE NEWSWIRE) -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the...
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide)
19 mars 2015 02h11 HE
|
SANOFI
PARIS, March 19, 2015 (GLOBE NEWSWIRE) -- Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk...
Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
15 mars 2015 11h14 HE
|
SANOFI
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine
- Robust and consistent LDL-C lowering...
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin
11 août 2014 01h12 HE
|
SANOFI
PARIS and VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide...
First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia
10 juil. 2014 19h07 HE
|
SANOFI
- 88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of world's first phase III efficacy study published in The Lancet -
- Two thirds reduction in hospitalization observed...
Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
09 juil. 2014 17h09 HE
|
SANOFI
PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b...
Sanofi Reports Positive Phase 3 Results for Toujeo(R)
14 juin 2014 13h09 HE
|
SANOFI
Sanofi Reports Positive Phase 3 Results for Toujeo®
(insulin glargine [rDNA origin] injection, 300 U/mL)
- Meta-analysis of three late-stage trials in people with type 2 diabetes shows...
Sanofi and Lilly announce licensing agreement for Cialis(R) (tadalafil) OTC
28 mai 2014 00h08 HE
|
SANOFI
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
- Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after...
Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization
05 mai 2014 01h06 HE
|
SANOFI
- Shan5(TM) is the first vaccine jointly developed by the Indian company
and its parent company Sanofi Pasteur -
- WHO's decision allows for the purchase of Shan5(TM) by United Nations agencies...
Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus(R) and Lantus(R) SoloStar(R)
30 janv. 2014 17h12 HE
|
SANOFI
PARIS, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( "Lilly") on January 30, 2014 in the...